A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2017
At a glance
- Drugs BGB 324 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
- 01 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
- 09 Jun 2017 Status changed from planning to not yet recruiting.
- 14 Mar 2017 New trial record